Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04104243 · ClinicalTrials.gov registry record · NA

Power-Up: An Effectiveness Trial of the Diabetes Prevention Program

A NA study of Type 2 Diabetes and Pre Diabetes, sponsored by Albert Einstein College of Medicine.

Completed
Registry status
NA
Development phase
301
Enrollment target
1
Study location

NCT04104243 is a NA study of Type 2 Diabetes and Pre Diabetes that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 301 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04104243, a NA study of Type 2 Diabetes and Pre Diabetes, has completed, sponsored by Albert Einstein College of Medicine.

COMPLETED
Registry status
NA
Development phase
301 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to address the risk of diabetes among men by creating a Diabetes Prevention Program (DPP) tailored to men.

Interventions

  • OTHER Men-Tailored DPP (Power-Up)

Study Locations (1)

New York

  • Albert Einstein College of Medicine - The Bronx

Trial Details

FieldValue
Enrollment Target 301 participants
Start Date 2021-08-09
Est. Completion 2025-02-07
Phase NA

Sponsor

Albert Einstein College of Medicine

175 total trials

What the Registry Record Tells You About NCT04104243

The ClinicalTrials.gov registry entry for NCT04104243 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (73% lower). The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Men-Tailored DPP (Power-Up) is the first listed.

NCT04104243 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT04104243 about?

NCT04104243 is a clinical study titled "Power-Up: An Effectiveness Trial of the Diabetes Prevention Program". The goal of this study is to address the risk of diabetes among men by creating a Diabetes Prevention Program (DPP) tailored to men.

What is the current status of trial NCT04104243?

This trial is currently completed. It is a NA study. The enrollment target is 301 participants. The study started on 2021-08-09. Estimated completion is 2025-02-07.

What conditions does trial NCT04104243 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Pre Diabetes.

What interventions are being tested in trial NCT04104243?

The interventions under investigation include: Men-Tailored DPP (Power-Up) (OTHER).

Who is sponsoring clinical trial NCT04104243?

This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04104243 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.